Iwona Lugowska, MD, PhD, is a clinical oncologist in the Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology (MSCMI), and in the Department of Epidemiology, Institute of Mother and Child, Warsaw, Poland.
In 2010 she received a PhD for research on the prognostic factors in osteosarcoma. Dr Lugowska is responsible for the establishment of the Early Phase Clinical Trial Unit in MSCMI.
Dr. Lugowska acts as the national coordinator of the EUROSARC (European Clinical trials in Rare Sarcomas) and IMMOMEC (IMmune MOdulating strategies for treatment of MErkel cell Carcinoma) projects, founded by the 7 Framework Program. She developed a Clinical Support System – IT solution for gastrointestinal stromal tumour (GIST) management.
Dr Lugowska has also received an award from the American Society of Clinical Oncology (ASCO) IDEA Program 2010, and visited the Memorial Sloan-Kettering Cancer Center in New York
She has also been selected for:
- the ECCO-AACR-EORTC-ESMO Workshop on Methods in Clinical Cancer Research 2015;
- the Talent in Oncology Program - GLOW Program 2011-2012;
- the fellowship of EORTC–NCI-ASCO Annual Meeting on Molecular Markers in Cancer 2011;
- and by the Netherlands Institute for Health Sciences in 2010 (Clinical Trials Methodology) and 2011 (Clinical Decision Making Modeling).
Dr. Lugowska is Chair of the ESMO Educational Publications Working Group, an active member of the EORTC Soft Tissue and Bone Sarcoma Group, and a member of Ethics Committee in MSMCI. Besides clinical practice, she has participated in academic and sponsored international clinical trials.
Her main fields of interest are sarcoma and melanoma research, as well as early phase clinical trials.